Coronavirus studies

See also: Flawed coronavirus studies, Hydroxychloroquine denial

Numerous coronavirus studies demonstrate the prophylactic and early use effectiveness of hydroxychloroquine (HCQ) against COVID-19, which are being ignored or downplayed for political reasons.

Here is a sampling of the growing list of valid studies confirming the effectiveness of hydroxychloroquine against COVID-19:

Compilation

A compilation of coronavirus studies demonstrates the effectiveness of early treatment by hydroxychloroquine.

Greek study suggests why HCQ is effective

A small Greek study indicates that HCQ is effective because it inhibits a hyperinflammatory reaction progression, if given in early stages of the disease.

Minnesota data mining study

The incidence rate and mortality from COVID-19 was found to be lower in patients on chronic hydroxychloroquine therapy, in a large Minnesota healthcare system.

Between April 1, 2019 and March 31, 2020, the database contained 1,271,014 unique patient encounters, including a total of 2945 COVID-19 tests, of which 125 (4.24%) were positive.

Among the tests performed, 124 (4.35%) were positive for COVID-19 while not having taken hydroxychloroquine, while 96 tests were performed in patients with existing hydroxychloroquine prescriptions and only one (1.04%) was positive.

Two COVID-19 patients not on hydroxychloroquine died, while no COVID-19 patients not on hydroxychloroquine died.

Hydroxychloroquine appears to be effective against COVID-19 both as a prophylaxis and as early treatment.

French study

In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."